A GENETIC TEST TO PREDICT ANTI-TNF DRUG RESPONSE

David Gibson; AJ Bjourson; Cathy McGeough; Martin A Crockard; John V. Lamont

A GENETIC TEST TO PREDICT ANTI-TNF DRUG RESPONSE

David Gibson (Inventor), AJ Bjourson (Inventor), Cathy McGeough (Inventor), Martin A Crockard (Inventor), John V. Lamont (Inventor)

Research output: Patent

Abstract

This invention relates to predicting a subject's responsiveness to biologic therapy of rheumatoid arthritis. The invention provides a method for predicting responsiveness to anti- tumour necrosis factor therapy of rheumatoid arthritis in a subject, the method comprising the steps of: (a) Providing a biological sample; (b) detecting the presence, absence, or quantitative level of a first marker or an expression product thereof, wherein the first marker is at the HLA DRB1 gene; (c) detecting the presence, absence, or quantitative level of a second marker, or an expression product thereof, wherein the second marker is at the CD226 gene; (d) correlating the presence, absence, or quantitative level of the first marker and the presence, absence, or quantitative level of the second marker; to the predicted responsiveness to anti- tumour necrosis factor therapy of rheumatoid arthritis in the subject.

Original language	English
Patent number	WO2021234172A1
IPC	C12Q1/6883
Priority date	22/05/20
Filing date	21/05/20
Publication status	Published (in print/issue) - 25 Nov 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://worldwide.espacenet.com/patent/search/family/071406200/publication/WO2021234172A1?q=gibson%20ulsterLicence: Unspecified

Cite this

@misc{7dd78b95bb954284bfbe8a705d8a8f47,

title = "A GENETIC TEST TO PREDICT ANTI-TNF DRUG RESPONSE",

abstract = "This invention relates to predicting a subject's responsiveness to biologic therapy of rheumatoid arthritis. The invention provides a method for predicting responsiveness to anti- tumour necrosis factor therapy of rheumatoid arthritis in a subject, the method comprising the steps of: (a) Providing a biological sample; (b) detecting the presence, absence, or quantitative level of a first marker or an expression product thereof, wherein the first marker is at the HLA DRB1 gene; (c) detecting the presence, absence, or quantitative level of a second marker, or an expression product thereof, wherein the second marker is at the CD226 gene; (d) correlating the presence, absence, or quantitative level of the first marker and the presence, absence, or quantitative level of the second marker; to the predicted responsiveness to anti- tumour necrosis factor therapy of rheumatoid arthritis in the subject.",

author = "David Gibson and AJ Bjourson and Cathy McGeough and Crockard, {Martin A} and Lamont, {John V.}",

year = "2021",

month = nov,

day = "25",

language = "English",

type = "Patent",

note = " WO2021234172A1; C12Q1/6883",

}

TY - PAT

T1 - A GENETIC TEST TO PREDICT ANTI-TNF DRUG RESPONSE

AU - Gibson, David

AU - Bjourson, AJ

AU - McGeough, Cathy

AU - Crockard, Martin A

AU - Lamont, John V.

PY - 2021/11/25

Y1 - 2021/11/25

N2 - This invention relates to predicting a subject's responsiveness to biologic therapy of rheumatoid arthritis. The invention provides a method for predicting responsiveness to anti- tumour necrosis factor therapy of rheumatoid arthritis in a subject, the method comprising the steps of: (a) Providing a biological sample; (b) detecting the presence, absence, or quantitative level of a first marker or an expression product thereof, wherein the first marker is at the HLA DRB1 gene; (c) detecting the presence, absence, or quantitative level of a second marker, or an expression product thereof, wherein the second marker is at the CD226 gene; (d) correlating the presence, absence, or quantitative level of the first marker and the presence, absence, or quantitative level of the second marker; to the predicted responsiveness to anti- tumour necrosis factor therapy of rheumatoid arthritis in the subject.

AB - This invention relates to predicting a subject's responsiveness to biologic therapy of rheumatoid arthritis. The invention provides a method for predicting responsiveness to anti- tumour necrosis factor therapy of rheumatoid arthritis in a subject, the method comprising the steps of: (a) Providing a biological sample; (b) detecting the presence, absence, or quantitative level of a first marker or an expression product thereof, wherein the first marker is at the HLA DRB1 gene; (c) detecting the presence, absence, or quantitative level of a second marker, or an expression product thereof, wherein the second marker is at the CD226 gene; (d) correlating the presence, absence, or quantitative level of the first marker and the presence, absence, or quantitative level of the second marker; to the predicted responsiveness to anti- tumour necrosis factor therapy of rheumatoid arthritis in the subject.

M3 - Patent

M1 - WO2021234172A1

Y2 - 2020/05/21

ER -

A GENETIC TEST TO PREDICT ANTI-TNF DRUG RESPONSE

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this